| ¿µ¹® | sural nerve | ÇÑ±Û | ÀåµýÁö½Å°æ |
|---|---|---|---|
| ¼³¸í | ¾ÈÂÊÀåµýÁöÇÇºÎ½Å°æ ¹× ¿ÂÀåµýÁö½Å°æÀÇ ±³ÅëÁö¿¡¼ ½ÃÀÛÇÏ¿© °¡ÂʹèÂÊÇÇºÎ½Å°æ ¹× °¡Âʹ߲ÞÄ¡°¡ÁöÀÇ °¡Áö¸¦ ³½´Ù. ³Ò´Ù¸® µîÂÊÀÇ ÇǺÎ, ¹ß²ÞÄ¡¿Í ¹ßÀÇ °¡ÂÊÀÇ ÇǺΠ¹× °üÀý¿¡ ºÐÆ÷Çϸç, ÀÏ¹Ý °¨°¢¼º ±â´ÉÀ» ÇÑ´Ù. |
||
| ¿µ¹® | spinal nerve | ÇÑ±Û | ô¼ö½Å°æ |
|---|---|---|---|
| ¼³¸í | ô¼öÀÇ ¾Õ»Ô¿¡¼ Ãâ¹ßÇÏ´Â ¿îµ¿½Å°æ°ú µÞ»ÔÀ¸·Î µé¾î¿À´Â °¨°¢½Å°æÀÌ ÇÕÃļ Çü¼ºµÇ´Â ½Å°æÀ¸·Î¼ ÃÑ 31½ÖÀÌ Á¸ÀçÇÔ. ¸ñ»À½Å°æÀÌ 8½Ö, ÀÚµî»À½Å°æÀÌ 12½Ö, Ç㸮»ÀÀÇ ½Å°æÀÌ 5½Ö, ¾ûÄ¡»ÀÀÇ 6½ÖÀ» ÀÌ·ë. |
||
| NGFB | nerve growth factor beta |
|---|---|
| NGFG | nerve growth factor gamma |
| NGFIA | nerve growth factor-induced clone A |
| NGFIC | nerve growth factor-induced clone C |
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
| fibroblast growth factor, acidic | <chemical> A growth factor which has been isolated from a variety of cells. It contains 154 amino acid residues and has potent heparin-binding activity. Heparin potentiates the biological activities of afgf. The growth factor is an extremely potent inducer of DNA synthesis in a variety of normal diploid mammalian cell types from mesoderm and neuroectoderm lineages and also has chemotactic and mitogenic activities. Chemical name: Fibroblast growth factor (human brain acidic protein moiety reduced) (12 Dec 1998) |
|---|---|
| fibroblast growth factor, basic | A single-chain polypeptide of approximately 15-16 kD which has been isolated from a variety of cells. It has a 55% amino acid residue identity to acidic fibroblast growth factor and has potent heparin-binding activity. However, in contrast to the acidic fibroblast growth factor, heparin does not potentiate the biological activities of bfgf. The growth factor is an extremely potent inducer of DNA synthesis in a variety of normal diploid mammalian cell types from mesoderm and neuroectoderm lineages and promotes cellular differentiation in vitro. (12 Dec 1998) |
| nerve growth cone | <cell biology> A specialised region at the tip of a growing neurite that is responsible for sensing the local environment and moving toward the neuron's target cell. Growth cones are hand shaped, with several long filopodia that differentially adhere to surfaces in the embryo. Growth cones can be sensitive to several guidance cues, for example: surface adhesiveness, growth factors, neurotransmitters and electric fields (galvanotropism). (18 Nov 1997) |
| nerve growth factors | Factors which enhance the growth potentialities of sensory and sympathetic nerve cells. (12 Dec 1998) |
| communicating branches of auriculotemporal nerve to facial nerve | <anatomy, nerve> Branches conveying fibres from the auriculotemporal nerve to the facial nerve. Synonym: rami communicantes nervi auriculotemporalis cum nervo faciali. (05 Mar 2000) |
| communicating branches of lingual nerve to hypoglossal nerve | <anatomy, nerve> Communicating branches between the lingual nerve (from mandibular nerve) and hypoglossal nerve forming a plexus on the hypoglossus muscle. Synonym: rami communicantes nervi lingualis cum nervo hypoglosso. (05 Mar 2000) |
| communicating branch of facial nerve with glossopharyngeal nerve | <anatomy, nerve> A small branch from the digastric branch of the facial nerve to the glossopharyngeal nerve. Synonym: ramus communicans cum nervo glossopharyngeo, Haller's ansa. (05 Mar 2000) |
| communicating branch of glossopharyngeal nerve with auricular branch of vagus nerve | <anatomy, nerve> A small branch of the glossopharyngeal nerve which joins the auricular branch of the vagus, conveying tactile fibres. Synonym: ramus communicans cum nervo glossopharyngeo, ramus communicans nervi glossopharyngei cum ramo auriculari nervi vagalis. (05 Mar 2000) |
| communicating branch of lacrimal nerve with zygomatic nerve | <anatomy, nerve> Nerve branch by which postsynaptic parasympathetic (secretomotor) fibres from the pterygopalatine ganglion are transferred from the zygomatic nerve to the lacrimal nerve (heretofore purely sensory) for distribution to the lacrimal gland. Synonym: ramus communicans nervi lacrimalis cum nervo zygomatico. (05 Mar 2000) |
| communicating branch of median nerve with ulnar nerve | <anatomy, nerve> Branch of median nerve joining the ulnar nerve in the hand; the anterior interosseous branch of the median nerve may also communicate with the ulnar nerve in the proximal forearm. Synonym: ramus communicans nervi mediani cum nervo ulnari. (05 Mar 2000) |
| communicating branch of superior laryngeal nerve with recurrent laryngeal nerve | <anatomy, nerve> Branch of internal branch of superior laryngeal nerve communicating with the recurrent laryngeal nerve in the wall of the laryngopharynx supplying sensory fibres to the latter. Synonym: ramus communicans nervi laryngei recurrentis cum ramo laryngeo interno, ramus communicans nervi laryngei superioris cum nervo laryngeo recurrenti, Galen's anastomosis, Galen's nerve. (05 Mar 2000) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|